24–25 February 2022
![]() |
![]() |
![]() |
![]() |
PO-07 | Clinical and epidemiological characteristics of Chronic Viral Hepatitis in Kazakhstan: data from Unified Nationwide Electronic Healthcare System 2014-2019 | Dmitriy Syssoyev | ![]() |
![]() |
|||
PO-18 | Are men who have sex with men (MSM) in Europe protected from Hepatitis A and B? Results from the European MSM internet survey (EMIS-2017) | Michael Brandl | ![]() |
![]() |
|||
PO-21 | HCV micro-elimination strategies for the PWUD population of the Balearic Islands | Jeffrey Lazarus | ![]() |
![]() |
|||
PO-26 | Low hepatitis C virus-viremia prevalence yet continued barriers to direct-acting antiviral treatment in people living with HIV in the Netherlands | Cas Isfordink | ![]() |
![]() |
|||
PO-27 | The prevalence of Hepatitis B in the UK: a systematic review | Sema Mandal | ![]() |
![]() |
|||
PO-28 | Mortality rates among individuals with laboratory diagnosed hepatitis B virus (HBV) infection: England, 1999-2018 | Sema Mandal | ![]() |
![]() |
|||
PO-36 | A model for a pharmacist-led point-of-care hepatitis C treatment service in outreach settings | Jacob Smiles | ![]() |
![]() |
|||
PO-39 | Immunity to hepatitis A and hepatitis B among men who have sex with men (MSM) attending sexual health clinics in London and the North of England, 2017-18 | Sema Mandal | ![]() |
![]() |
|||
PO-52 | The Mobile pathway, an opportunity in providing Hepatitis C services, during the challenging times of COVID-19 | Anne Manjalee Liyanage | ![]() |
![]() |
|||
PO-56 | Antenatal hepatitis C testing and care in maternity services in England, a national survey | Amoolya Vusirikala | ![]() |
![]() |
|||
PO-57 | Primary care physician adoption of hepatitis C virus treatment in United States Medicaid programs | Shashi Kapadia | ![]() |
![]() |
|||
PO-63 | FIB-5 and/or FIB-4 index for hepatic fibrosis assessment in chronic hepatitis B patients | Mohamed Abdel-Samiee | ![]() |
![]() |
|||
PO-64 | Trends in hepatitis C treatment and chronic prevalence over the last decade among people who inject drugs | Eva Emanuel | ![]() |
![]() |
|||
PO-66 | FOCUS Project: preliminary results toward Hepatitis C Virus screening and elimination in Almería, Spain | Anny Camelo Castillo | ![]() |
![]() |
|||
PO-69 | Screening for hepatitis C virus reinfection using a behaviour-based risk score among HIV-positive men who have sex with men | Kris Hage | ![]() |
![]() |
|||
PO-73 | Combined COVID-19 vaccination and hepatitis C virus and HIV screening intervention for high-risk populations at a mobile testing unit in Madrid, Spain | Jeffrey V Lazarus | ![]() |
![]() |
|||
PO-75 | Demonstrating control of perinatal transmission of hepatitis B in the UK: a low prevalence country with universal antenatal screening and ive neonatal immunisation programmes | Sema Mandal | ![]() |
![]() |
|||
PO-76 | Community values and preferences regarding decentralisation and task-shifting of HCV services - results from an international online survey | Cary James | ![]() |
![]() |
|||
PO-78 | Demographic characteristics and viral diversity in hepatitis B infected pregnant women in England: implications for control of maternal to child transmission | Eleanor Clarke | ![]() |
![]() |
|||
PO-82 | Enhancing Universal Hepatitis B and C Screening via the Electronic Medical Record: A Case Study | Mageras Anna | ![]() |
![]() |
|||
PO-84 | Outcome of Hepatitis C Virus co-infection treatment among Human Immunodeficiency Virus-infected people who inject drugs: an Egyptian real-life experience. | ahmed cordie | ![]() |
![]() |
|||
PO-88 | Approaches for a Hepatitis C-free city: preliminary results | Angelica Luque | ![]() |
![]() |
|||
PO-89 | Direct acting antiviral treatment for chronic hepatitis C are successful in Egyptian patients with chronic hepatitis C virus infection after a geographically focused, community-based HCV screening | Mohamed Abdel-Samiee | ![]() |
![]() |
|||
PO-92 | Hepatitis C virus micro-elimination approach in vulnerable population in the South of Spain | Jesús Aranda López | ![]() |
![]() |
|||
PO-94 | Screening for hepatitis C virus in high risk categories of Romanian population and updated prevalence data | Speranta Iacob | ![]() |
![]() |
|||
PO-97 | Microelimination of Hepatitis C in patients with substance use disorders | Ruben Carvalho | ![]() |
![]() |
|||
PO-98 | Screening for hepatitis B virus in high risk categories of Romanian population and updated prevalence data | Speranta Iacob | ![]() |
![]() |
|||
PO-99 | No reinfections: elimination is feasible in drug adicctions users | Esther Rodríguez Candelaria | ![]() |
![]() |
|||
PO-105 | Safety and efficacy of crushed sofosbuvir/velpatasvir in hepatitis C infected patients - a case series | Shobha Joshi | ![]() |
![]() |
|||
PO-107 | Going, going, gone? Routine Emergency Department hepatitis C testing can drive and monitor elimination | Kate Drysdale | ![]() |
![]() |
|||
PO-111 | Estimated prevalence of chronic hepatitis B in Denmark | Signe Bollerup | ![]() |
![]() |
|||
PO-112 | Framework for hepatitis C virus (HCV) Micro-Elimination in Ho Chi Minh City (HCMC), Vietnam: A Path to National HCV Elimination | Thanh Kim | ![]() |
![]() |
|||
PO-113 | Is it possible a real Point-Of-Care? Feasibility evaluation of telemedicine project to overcome the last barriers to treatment in PWIDs. | Daniela Maggi | ![]() |
![]() |
|||
PO-114 | Characteristics of childhood hepatitis B diagnosed cases reported to the national enhanced surveillance system, England 2017-2021 | Eleanor Clarke | ![]() |
![]() |
|||
PO-115 | HCV elimination among People Who Use Drug in Rome outside the hospital setting is possible during the COVID19 pandemic. | Elisabetta Teti | ![]() |
![]() |
|||
PO-117 | What can Europe learn from HCP knowledge and attitudes towards hepatitis A vaccination in the US? | Anar ANDANI | ![]() |
![]() |
|||
PO-118 | Point of care screening tests for hepatitis B and commitment of a dedicated nurse lead to successful linkage to care of ethnic minorities | Axelle Vanderlinden | ![]() |
![]() |
|||
PO-121 | A model for detection and linkage to care of hepatitis C infected persons in prisons in Croatia | Lucija Virovic Jukic | ![]() |
![]() |
|||
PO-122 | The Elimination of hepatitis C by the Cherokee Nation | Jorge Mera | ![]() |
![]() |
|||
PO-123 | implementing a simplified model of care for hepatitis c virus micro-elimination among people living with human immunodeficiency virus who inject drugs in Egypt | Rahma Mohamed | ![]() |
![]() |
|||
PO-124 | a single centre 2020 view of blood borne viruses and risk behaviour in male irish prisoners | CATHAL CLIFFORD | ![]() |
![]() |
|||
PO-128 | Evidence of hepatitis B virus (HBV) horizontal transmission and a significant proportion of adults remaining at high risk of horizontal HBV transmission are barriers to HBV elimination in Ho Chi Minh City (HCMC), Vietnam | Thanh Kim | ![]() |
![]() |
|||
PO-136 | Hepatitis C virus in people who inject drugs at the Needle and Syringe Program in Uppsala, Sweden | Elsa Kagstrom | ![]() |
![]() |
|||
PO-137 | Phyloepidemiological analysis of antiviral resistance to NS5A inhibitors in subtype 1a in England post-rollout of direct acting antivirals | Daniel Bradshaw | ![]() |
![]() |
|||
PO-138 | Combined telephone and home assessment and home treatment delivery improves drug service client access to hepatitis c care and treatment uptake during the COVID-19 pandemic | Natasha Baker | ![]() |
![]() |
|||
PO-139 | Hepatitis B virus vaccination among people with human immunodeficiency virus in the Netherlands | Anders Boyd | ![]() |
![]() |
|||
PO-140 | Update on hepatitis A in Europe a systematic review on outbreaks and burden of disease in 11 countries, 20012021 | Kassiani Mellou | ![]() |
![]() |
|||
PO-141 | Covid-19 pandemic: a significant barrier for hepatitis c elimination for people who use drugs (PWUD) in Greece | Pinelopi Antonakaki | ![]() |
![]() |
|||
PO-143 | Estimating rates of hepatitis C virus reinfection among patients receiving antiviral treatment in England | Matthew Hibbert | ![]() |
![]() |
|||
PO-144 | Hepatitis C virus test positivity among pregnant women in England between 2016-2017 | Matthew Hibbert | ![]() |
![]() |
|||
PO-147 | Seroprevalence of vaccine derived Hepatitis B antibodies in Germany: results from the German Health Survey for Children and Adolescents, 2014-2017 | Ida Sperle | ![]() |
![]() |
|||
PO-149 | Implementation of rapid point-of-care diagnostic systems to support HCV micro-elimination strategies in a tertiary hospital in Spain. | Antonio Madejón | ![]() |
![]() |
|||
PO-150 | Clinical characteristics and survival of patients with cirrhosis and hepatocellular carcinoma in The Gambia | Erwan Vo Quang | ![]() |
![]() |
|||
PO-155 | How should reinfection rates be measured and presented? Pitfalls and practical lessons from the Trap HepC project | Magnus Gottfredsson | ![]() |
![]() |
|||
PO-161 | Effectiveness of non-nurse, non-doctor Community Liaison Officer programme in testing and treating hepatitis C in homeless populations | F Javier Vilar | ![]() |
![]() |
|||
PO-167 | National Hepatitis Elimination Profiles: Progress Towards HBV and HCV Elimination in the Americas | Vanessa Nunez | ![]() |
![]() |
|||
PO-168 | Hepatitis C virus treatment uptake among marginalized people who inject drugs: a registry based study | Kristian Malme | ![]() |
![]() |
|||
PO-172 | The Canadian real-world 8 years experience with DAA-based regimens in genotype 3: Preliminary data | Isaac Ruiz | ![]() |
![]() |
|||
PO-179 | Hepatitis C screening in a psychiatric emergency department: 8-months results | Ana Barreira | ![]() |
![]() |
|||
PO-183 | TESTATE C Plus: an online self-sampling intervention for hepatitis C in gay, bisexual and other men who have sex with men and trans women in Spain | Cristina Agustí | ![]() |
![]() |
|||
PO-195 | To reconvene patients who were lost to follow-up is a useful strategy to eliminate Hepatitis C Virus. Results from the multicenter French study RECONVOCC. | Armand Abergel | ![]() |
![]() |
|||
PO-199 | Hepatitis A and B Infection and Vaccination among MSM in Ireland: an Analysis of the Findings from the European MSM Internet Survey 2017 (EMIS-2017) | Philippa White | ![]() |
![]() |
|||
PO-202 | Lack of Hepatitis B vaccination among high-risk populations: A single-center study in an addiction treatment center | Franois Villeret | ![]() |
![]() |
|||
PO-203 | Mind the Gap: Preliminary evaluation of the prevention of mother-to-child transmission of Hepatitis B care cascade in rural western Uganda | Sahal Thahir | ![]() |
![]() |
|||
PO-204 | Contact tracing in networks of people who inject drugs with Hepatitis C is the most efficient testing strategy to maintain Hepatitis C elimination post 2030 | RYan Buchanan | ![]() |
![]() |
|||
PO-207 | Targeted immunotherapy with heterologous prime-boost and adjuvanted hepatitis B core (HBc)/surface (HBs) proteins in adult chronic hepatitis B patients showed positive HBc- and HBs-specific CD8 and CD4 T cell responses in a phase I/II trial | Kristien Swinnen | ![]() |
![]() |
24–25 February 2022
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|